Chae Hyeong Lee

Dr. Chae Hyeong Lee


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
JKJeongyun Kim
Jeongyun Kim
CLChae Hyeong Lee
Chae Hyeong Lee
GYGa Won Yim
Ga Won Yim
Surgical treatment is commonly employed to treat patients with gynecologic cancer, although surgery itself may function as a stressor, reducing the patients’ functional capacity and recovery. Prehabilitation programs attempt to improve patients’ overall health and baseline function prior to surgery, thereby enhancing recovery and lowering morbidity. In recent years, prehabilitation has come to primarily refer to multimodal programs that combine physical activity, nutritional support, psychological well-being, and other medical interventions. However, the specific methods of implementing prehabilitation and measuring its effectiveness are heterogeneous. Moreover, high-level evidence regarding prehabilitation in gynecologic cancer surgery is limited. This review provides a summary of multimodal prehabilitation studies in gynecologic oncologic surgery. Enhanced postoperative recovery, lower postoperative complications, lower rate of blood transfusions, and faster gastrointestinal functional recovery have been reported after multimodal prehabilitation interventions. Patients and healthcare professionals should recognize the importance of prehabilitation in the field of gynecologic oncologic treatment, based on the emerging evidence. In addition, there is a need to establish an appropriate target group and construct a well-designed and tailored prehabilitation program.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
BYBo Seong Yun
Bo Seong Yun
KLKwang-Beom Lee
Kwang-Beom Lee
KLKeun Ho Lee
Keun Ho Lee
HCHa Kyun Chang
Ha Kyun Chang
Jooyoung KimJooyoung Kim
Jooyoung Kim
OIon behalf of Korean Gynecologic Oncology Group (KGOG) Investigators
on behalf of Korean Gynecologic Oncology Group (KGOG) Investigators
Bulky or multiple lymph node (LN) metastases are associated with poor prognosis in cervical cancer, and the size or number of LN metastases is not yet reflected in the staging system and therapeutic strategy. Although the therapeutic effects of surgical resection of bulky LNs before standard treatment have been reported in several retrospective studies, well-planned randomized clinical studies are lacking. Therefore, the aim of the Korean Gynecologic Oncology Group (KGOG) 1047/DEBULK trial is to investigate whether the debulking surgery of bulky or multiple LNs prior to concurrent chemoradiation therapy (CCRT) improves the survival rate of patients with cervical cancer IIICr diagnosed by imaging tests. The KGOG 1047/DEBULK trial is a phase III, multicenter, randomized clinical trial involving patients with bulky or multiple LN metastases in cervical cancer IIICr. This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The secondary endpoints will be 3-year overall survival rate, treatment-related complications, and accuracy of radiological diagnosis of bulky or multiple LNs. ClinicalTrials.gov Identifier: NCT05421650; Clinical Research Information Service Identifier: KCT0007137.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
CLChae Hyeong Lee
Chae Hyeong Lee
EKEun Jung Kim
Eun Jung Kim
MLMin Hee Lee
Min Hee Lee
GYGa Won Yim
Ga Won Yim
KKKyeong Joon Kim
Kyeong Joon Kim
JRJu-Won Roh
Ju-Won Roh
Lee CH, et al. J Korean Med Sci. 2020 May;35(24):e207. https://doi.org/10.3346/jkms.2020.35.e207

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SPSun Min Park
Sun Min Park
Chel Hun ChoiChel Hun Choi
Chel Hun Choi
KKKidong Kim
Kidong Kim
HKHyojin Kim
Hyojin Kim
SKSe Ik Kim
Se Ik Kim
CLChae Hyeong Lee
Chae Hyeong Lee
Park SM, et al. J Gynecol Oncol. 2026 ;37:e80. https://doi.org/10.3802/jgo.2026.37.e80

27 November 2023 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
MKMin-Jeong Kim
Min-Jeong Kim
GLGrace J. Ba Lee
Grace J. Ba Lee
ELEun Ji Lee
Eun Ji Lee
SLSeungmee Lee
Seungmee Lee
DCDoo Byung Chay
Doo Byung Chay
JRJu-Won Roh
Ju-Won Roh
Objective: This study aimed to examine whether the intraoperative use of Lugol's solution reduces the proportion of positive resection margins (RMs) using the data of women who underwent large loop excision of the transformation zone (LLETZ). Materials and Methods: A total of 1,751 consecutive women with cervical intraepithelial neoplasia (CIN) who underwent LLETZ with or without Lugol's solution were retrospectively retrieved from each database of 3 university hospitals in South Korea. Outcomes included positive RMs and residual disease pathologically confirmed within 6 months after LLETZ. Results: Positive RMs were noted in 345 cases (19.7%). Among 1,507 women followed up, residual disease was diagnosed in 100 cases (6.6%) (69/308 cases with positive RMs; 31/1,199 cases with negative RMs). The Lugol's solution group was less likely to have positive RMs (11.8% vs 25.5%, p < .01), to require additional surgical intervention (5.4% vs 10.2%, p < .01), and to have residual disease (4.9% vs 8.0%, p = .02). On multiple logistic regression analysis, Lugol's solution reduced the proportion of positive RMs (adjusted odds ratio [aOR], 0.31). Age (50 years or older; aOR, 1.64), preconization cervical cytology (aOR, 1.53), high-risk human papillomavirus (aOR, 1.75), and CIN 2 or 3 (aOR, 2.65) were independent risk factors for margin positivity (p < .01 for all except high-risk human papillomavirus of p = .05). Conclusions: Lugol's solution optimizes CIN treatment by reducing the proportion of positive RMs and residual disease after LLETZ.

15 June 2025 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Open access
DJDae Hoon Jeong
Dae Hoon Jeong
YKYong Beom Kim
Yong Beom Kim
KKKidong Kim
Kidong Kim
JLJong-Min Lee
Jong-Min Lee
DHDae Gy Hong
Dae Gy Hong
Min Kyu KimMin Kyu Kim
Min Kyu Kim
Aim: To evaluate the perioperative outcomes of patients with endometrial cancer meeting the Korean Gynecologic Oncology Group (KGOG) criteria who underwent surgery without lymph node dissection.Methods: This study included 153 patients who met the KGOG criteria: (1) endometrioid histology, (2) myometrial invasion 1 cm, and (5) serum CA125 ≤ 35 U/mL. The patients underwent surgery without lymph node dissection at 11 hospitals in Korea between February 2020 and May 2024. Perioperative outcomes were collected prospectively.Results: Among the 153 patients, 89 (58%) underwent surgery without lymph node removal, while 64 (42%) underwent surgery with lymph node removal. Minimally invasive surgery was performed in >90% of cases, with a conversion rate to laparotomy of 1%. The mean surgery time was 109.37 ± 37.67 min. Estimated blood loss was minimal (93.74 ± 93.13 mL), with a mean hemoglobin drop of 1.32 ± 1.01 g/dL. Transfusions were required in only three patients (2%). Postoperative hospital stays exceeded 2 days in 51% of cases. Lymph node metastasis was observed in just one case (1%). Adverse events included 52 grade 1 and 2 grade 2 events (e.g., headache, paresthesia). Patients undergoing lymph node removal (primarily sentinel lymph node biopsy) had significantly longer surgery times and postoperative hospital stays compared to those without lymph node removal.Conclusion: Surgery without lymph node dissection demonstrated excellent perioperative outcomes and minimal adverse events in patients meeting KGOG criteria.